Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01143259 · ClinicalTrials.gov registry record · NA
Intermountain Healthcare's Enhanced Recovery Protocol for Colon Surgery With and Without Alvimopan Use
A NA study, sponsored by Intermountain Health Care.
- Completed
- Registry status
- NA
- Development phase
- 274
- Enrollment target
NCT01143259 is a NA study that has completed, run by Intermountain Health Care. The registered enrollment target is 274 participants.
The verdict
NCT01143259, a NA study, has completed, sponsored by Intermountain Health Care.
- COMPLETED
- Registry status
- NA
- Development phase
- 274 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if the addition of alvimopan to our care process model for colon resection patients will decrease length of stay. The care process model is a combination of optimal IV fluid management, early feeding, early ambulation, patient education, and pain management.
Interventions
- DRUG Alvimopam
- DRUG 300 mg Polyethylene
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 274 participants |
| Start Date | 2010-05 |
| Est. Completion | 2012-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01143259
The ClinicalTrials.gov registry entry for NCT01143259 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 274 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Intermountain Health Care, which has 85 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Alvimopam is the first listed.
NCT01143259 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01143259 about?
NCT01143259 is a clinical study titled "Intermountain Healthcare's Enhanced Recovery Protocol for Colon Surgery With and Without Alvimopan Use". The purpose of this study is to determine if the addition of alvimopan to our care process model for colon resection patients will decrease length of stay. The care process model is a combination of optimal IV fluid management, early feeding, early ambulation, patient education, and pain management.
What is the current status of trial NCT01143259?
This trial is currently completed. It is a NA study. The enrollment target is 274 participants. The study started on 2010-05. Estimated completion is 2012-08.
What interventions are being tested in trial NCT01143259?
The interventions under investigation include: Alvimopam (DRUG), 300 mg Polyethylene (DRUG).
Who is sponsoring clinical trial NCT01143259?
This trial is sponsored by Intermountain Health Care, which has 85 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.